MORRISVILLE, N.C. , May 22, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer
MORRISVILLE, N.C. , May 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer
Highlights GAAP revenue of $1,163.4 million for the three months ended March 31, 2020 , representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency adjusted basis compared to the same period in 2019. Net new business awards of $1,531.6 million and $5,724.7 million for
Company Expects Aggregate First Quarter Results to Be in Line With Previously Issued Guidance Range First Quarter 2020 Earnings Call Scheduled for Thursday, April 30, 2020 MORRISVILLE, N.C. , April 07, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated
Alongside ACRO, Syneos Health to Provide Support for COVID-19 Testing Centers; Company Continues Public Service Educational Program to Address Ventilator Shortage MORRISVILLE, N.C. , April 03, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical
www.COVID-BiPAPInfo.com Provides Practical Information for Physicians on Innovative Use of BiPAP Machines – Already Available in Many Hospitals – to Potentially Delay or Remove Need for Mechanical Ventilation for Appropriate COVID-19 Patients Skipta Joins Syneos Health-Led Effort by Leveraging New
Highlights GAAP revenue of $1,213.0 million and $4,675.8 million for the three and twelve months ended December 31, 2019 , representing growth of 5.9% and 6.5% compared to the same periods in 2018, respectively. Adjusted revenue of $1,214.5 million and $4,682.2 million for the three and twelve
MORRISVILLE, N.C. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and year end 2019 financial results on Thursday, February 20, 2020 , prior to its earnings call at 8:00 a.m.
Omnipresence Platform Provides Biopharmaceutical Companies Advanced Analytics, AI and Cloud Innovations Powered by Microsoft MORRISVILLE, N.C. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced a strategic
MORRISVILLE, N.C. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer
